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Abstract
Background: Human chromosome 8q24 has been implicated in prostate tumorigenesis.
Methods: Consequently, we evaluated seven 8q24 sequence variants relative to prostate cancer (PCA) in a case-
control study involving men of African descent. Genetic alterations were detected in germ-line DNA from 195 incident 
PCA cases and 531 controls using TaqMan polymerase chain reaction (PCR).
Results: Inheritance of the 8q24 rs16901979 T allele corresponded to a 2.5-fold increase in the risk of developing PCA 
for our test group. These findings were validated using multifactor dimensionality reduction (MDR) and permutation 
testing (p = 0.038). The remaining 8q24 targets were not significantly related to PCA outcomes.
Conclusions: Although compelling evidence suggests that the 8q24 rs16901979 locus may serve as an effective PCA 
predictor, our findings require additional evaluation in larger studies.
Background
Prostate cancer (PCA) accounts for 25% of all diagnosed
cancer cases and was the second leading cause of cancer-
related deaths in 2009 among U.S. men [1]. Well-estab-
lished risk factors of PCA include age, family history of
PCA, and ethnicity. African American men carry a sub-
stantial portion of the disease burden and are 1.6- and
2.4-fold more likely to be diagnosed with PCA and die
from disease, respectively, relative to their Caucasian
counterparts [2]. This disparity may be partially attrib-
uted to a combination of genetic predisposition and envi-
ronmental exposures. Despite evidence supporting the
role of genetics in PCA etiology, the search for common
sequence variants as susceptibility markers has been
largely unrewarding. However, recent genome-wide asso-
ciation studies (GWAS) indicate that chromosome 8q24
is a region of interest for further exploration of health dis-
parity markers relative to PCA incidence and outcomes.
Several genetic variants or single nucleotide polymor-
phisms (SNPs) in the 8q24 region have been associated
with PCA risk in Caucasians; however, similar studies on
African Americans are only represented in a handful of
published reports [3-8]. Amundattoir and co-workers
(2006) demonstrated that the DG8S737- 8 microsatellite
was significantly associated with PCA risk and disease
progression in men of European and African descent [5].
The association signal of DG8S737- 8 in Caucasians has
been captured by rs1447295 or one of its linkage disequi-
librium equivalents. This was not the case for African
Americans, which suggests that the DG8S737- 8 micro-
satellite was either associated with increased PCA risk or
is significantly correlated with other 8q24 sequence vari-
ants not detected in a GWAS scan or HapMap project.
Two subsequent studies provide compelling evidence that
two 8q24 sequence variants, rs6983561 and rs16901979,
may be important PCA indicators for Caucasians and
African Americans [3,6]. Although the risk estimates for
rs16901979 were similar between Caucasians and African
Americans, this marker's higher prevalence among Afri-
can Americans may partially explain the greater PCA
incidence in this high-risk group. In fact, Gudmundson
and co-workers (2007) suggested that the rs16901979
SNP alone could account for a large fraction of PCA risk
among African Americans, as they had a considerably
high population-attributable risk associated with this
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marker (24%) relative to Caucasians [7]. Two other
sequence variants, rs4242382 and rs4242384, were signif-
icantly related to organ-confined or aggressive disease
when compared to disease-free men of European descent
[9-11].
Unfortunately, the impact of these two loci and other
8q24 markers (e.g., rs6983561, rs1447295, rs11934905,
rs16901979, and rs10090154) on PCA risk among men of
African descent remains largely unknown. Although the
8q24 rs10090154T allele confers a 1.7-fold increase in
PCA risk in a small case-control study set involving Afri-
can Americans (85 cases and 149 disease-free men), this
locus only reached borderline significance (OR = 1.69;
0.92-3.11).
T o clarify the role of 8q24 sequence variants in PCA
susceptibility among men of African descent, we sought
to confirm previous reports and generate new data on the
role of seven 8q24 sequence variants in PCA risk among
864 men of African descent (195 cases and 531 disease-
free men). To overcome sample size issues and control for
multiple comparisons, we used a multifactor dimension-
ality reduction (MDR) algorithm along with permutation
testing. This approach will aid future studies that analyze
different sequence variants within the 8q24 region to
decode health disparities in high-risk subgroups, espe-
cially PCA risk in men of African descent.
Methods
Study population
Between 2001 and 2005, 864 unrelated male residents
were recruited from the Washington, D.C. and Columbia,
SC areas through the Howard University Hospital (HUH)
Division of Urology or PCA screening programs. The
study population of men of African descent (i.e., self-
reported African Americans, East African Americans,
West African Americans, and Afro-Caribbean Ameri-
cans) consisted of 195 incident PCA cases and 531 con-
trols. PCA patients between the ages of 41 and 91 were
diagnosed within one year of enrollment. Following a
visit to the HUH Division of Urology for an annual PCA
screening exam or urinary symptoms, incident PCA
cases were identified by a urologist using a transrectal
ultrasound-guided biopsy [12]. Biopsy cores were
reviewed by members of the Department of Pathology at
the Howard University College of Medicine. PCA cases
were classified according to a well-established Gleason
scoring system [13]. Inclusion criteria of controls
included men older than 45 with a low prostate specific
antigen (PSA) level ≤ 4.0 ng/ml and normal digital rectal
exams (DREs) or biopsies. Individuals were excluded
from the current study if: they failed at least one diagnos-
tic test (i.e., PSA > 4.0 and/or irregular PSA), even though
they had a normal biopsy; or were diagnosed with benign
prostatic hyperplasia (BPH). Clinical characteristics
including Gleason score, PSA and age at diagnosis/enroll-
ment were obtained fr om medical recor ds, as summa-
rized in Table 1. The median age of 65.0 for PCA cases
(range: 41-91) was significantly older than that of disease-
free men [median = 53 yrs (45-89)]. Tumor grade, ranging
from 4-10, was collected for 59% of the cases (n = 115).
All study participants had DNA extracted from whole
blood and provided written informed consent for partici-
pation in genetic analysis studies under a protocol
approved by Howard University, the HUH Division of
Urology, and the University of Louisville Institutional
Review Board.
TaqMan allelic discrimination of 8q24 sequence variants
Polymorphisms detected in the 8q24 region were ascer-
tained using TaqMan Polymerase Chain Reaction (PCR)
allelic discrimination assays. The following seven alleles
were detected: (1) rs6983561 (A > C); (2) rs1447295 (G >
T); (3) rs4242384 (A > C); (4) rs4242382 (G > A); (5)
rs11934905 (G > A); (6)  rs16901979 (G > T); and (7)
rs10090154 (G > A). Each allelic discrimination assay
contained approximately 40 ng of germ-line DNA, 1×
Universal Master Mix (Applied Biosystems, Foster City,
CA), a 40× mixture containing 900 nM of each primer
(forward and reverse), and 200 nM of each probe (FAM
and VIC) to comprise a 5 μl reaction. To facilitate amplifi-
cation of regions containing the aforementioned 8q24
SNPs, primers and probes were designed in our labora-
tory using sequences provided by NCBI [14] and placed
into the FileBuilder software (Applied Biosystems). PCR
reactions were carried out using the ABI Prism 7900HT
Sequence Detection System (Applied Biosystems). The
thermocycling settings consisted of two holds at 50°C for
2 min and 95°C for 10 min, followed by 40 cycles at 95°C
for 15 sec/cycle and 1 min at 60°C. The fluorescent inten-
sity emitted from the probes was measured using the ABI
7900 sequence detection system and assigned genotypes
with the SDS 2.2.1 software (Applied Biosystems). To
minimize misclassification bias, laboratory technicians
were blinded to the case status of study participants.
Based on 24 non-DNA template controls per batch analy-
sis, the percent cross-contamination during sample han-
dling was less than 4.7%. Duplicate genotyping was
performed on 72 randomly selected samples for quality
control purposes, resulting in concordance rates of ≥
97.5%. The genotype call rates ranged between 89.6 and
96.2% across the seven SNPs with a median value of
92.3%. Subjects (n = 62) with 4 or more missing SNP
values across the 7 SNPs were removed from the final
analysis.
Ancestry Markers
One hundred ancestry autosomal markers were included
to account for potential population stratification amongBenford et al. BMC Cancer 2010, 10:334
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our admixed population of self-reported African-Ameri-
cans, West African Americans, East African Americans,
and Afro-Caribbean Americans, as previously described
[15]. Study participants were grouped from lowest to
highest genetic West African ancestry, with scores rang-
ing from 0 to 100%. This marker was assembled using
DNA from self-identified African-Americans (Coriell
Institute for Medical Research, n = 96), Yoruban West
Africans (HapMap, n = 60), West Africans (Bantu and
Nilo Saharan speakers, n = 72), Europeans (New York
City, n = 24), and Centre d'Etude du Polymorphisme
Humain (CEPH) Europeans (HapMap Panel, n = 60).
Individuals with a high degree of West African ancestry
greater than or equal to 25% were included in the current
study.
Screening for single gene markers predictive of PCA risk 
using conventional Logistic Regression (LR) Analysis
To assess whether inheritance of at least one variant 8q24
allele was associated with an elevated risk of developing
PCA, we tested for significant differences in the distribu-
tion of seven 8q24 genotypes between 195 cases and 531
controls using the chi-square test of homogeneity. Asso-
ciations between PCA risk and 8q24 sequence variants,
expressed as odds ratios (ORs) and corresponding 95%
confidence intervals (CIs), were estimated using uncondi-
tional multivariate LR models adjusted for potential con-
founders (age, PSA, and West African ancestry). All
reported risk estimates and 95% CIs for the selected 8q24
loci used the following as reference genotypes: (1)
rs6983561 (A/A); (2) rs1447295 (G/G); (3) rs4242384 (A/
A);  (4)  rs4242382 (G/G); (5)  rs11934905 (G/G); (6)
rs16901979 (G/G); and (7)  rs10090154 (G/G). For
rs11934905, hetero- and homozygotes (AA + GA) were
combined due to the low frequency of the minor allele.
Test for trend included genotypes as ordinal variables.
Statistical significance was assessed using a P-value <
0.05. All chi-square tests and LR analyses were conducted
using the SAS 9.1.3 software (SAS Institute Inc., Cary,
NC).
Validation of main effects using MDR
Multifactor dimensionality reduction (MDR) was used to
evaluate and validate main effects associated with PCA
Table 1: Patient and Tumor Characteristics
Characteristics Cases Controls P-valuea
No. of Participants, n 195 531 ---
Age (yrs)
Median (range) 65.0 (41-91) 53.0 (45-89) < 0.0001
PSA in ng/ml
Median (range) 7.0 (0.01-5,000) 1.08 (0.01-3.9) < 0.0001
< 2.0, n (%) 43 (22.0) 464 (87.4)
2.0-4.0 12 (6.2) 67 (12.6)
> 4.0 140 (71.8) 0 (0.0)
Gleason Score n (%)
4 15 (13.0)
5 11 (9.6)
6 31 (26.9)
7 37 (32.2)
85  ( 4 . 4 )
9 12 (10.4)
10 4 (3.5)
Global West African Ancestry
Median (SD) 0.788 (0.253-0.937) 0.734 (0.255-0.946) 0.0273
Abbreviations: PSA, prostate specific antigen
aDifferences in median age, PSA levels (ng/ml), and West African Ancestry levels comparing cases and controls were tested using the 
Wilcoxon rank sum.Benford et al. BMC Cancer 2010, 10:334
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risk. This algorithmic tool aids in the identification of
high-risk markers using a cross validation strategy to esti-
mate the classification and prediction accuracy of indi-
vidual factor models [16,17]. MDR is a data-mining
platform that readily overcomes sample size limitations
often encountered by parametric statistical methods (e.g.,
LR analysis) by collapsing high-dimensional genetic data
into a single dimension. For this study, single factor loci
were classified into high-risk and low-risk groups, which
permitted the investigation of individual effects of variant
8q24 alleles in relation to PCA risk using a cross-valida-
tion and permutation testing scheme. MDR was utilized
to generate a single model that maximized the number of
individuals with the proper risk assignment. The best
8q24 sequence variant was selected among the seven loci
that minimized the prediction error as well as maximized
the cross validation consistency (CVC) and average test-
ing accuracy (ATA). To evaluate the number of times the
same single factor model was identified in each possible
9/10ths of the data, the average CVC (based on a scale
from 0-100%) from the observed data was compared to
the distribution of average consistencies under the null
hypothesis of no association. Validation of models as
effective predictors of PCA susceptibility was derived
empirically from 10,000 permutations. This approach
accounted for multiple testing issues as long as the entire
model fitting procedure was repeated for each random-
ized dataset to provide an opportunity to identify false-
positives. We considered MDR permutation results to be
statistically significant at the 0.05 level.
Results
Patient & Tumor Characteristics
The patient and tumor characteristics in the current
study are summarized in Table 1. Cases were significantly
older than controls and had higher PSA levels. There was
significant difference in median West African genetic
ancestry estimates when comparing cases and controls (P
= 0.0273).
Prevalence of 8q24 variant alleles among men of African 
descent
Our laboratory successfully completed the analysis of
seven 8q24 sequence variants among 864 men of African
descent (195 PCA cases and 531 controls). Inheritance of
at least one minor 8q24 minor allele was fairly common
among controls with frequencies ranging between 4.0
and 66.3%, as detailed in Table 2. These findings were
comparable to those observed in other men of African
descent sub-groups [3,18-20,14].
Association between 8q24 and PCA
The independent effects of genetic variations detected
within the 8q24 region were analyzed relative to PCA
susceptibility using MDR and unconditional LR multivar-
iate models adjusted for age and West African ancestry
(Table 2). We evaluated whether inheritance of at least
one minor 8q24 allele, e.g., rs6983561 (AC + CC),
rs1447295 (GT + TT), rs4242384 (AC + CC), rs4242382
(GA + AA), rs11934905 (GA + AA), rs16901979 (GT +
TT), or rs10090154 (GA + AA), was associated with PCA
risk. We observed significant main effects of sequence
variants localized to chromosome 8q24 in relation to
PCA risk. Notably, individuals who possessed the
rs6983561 C (OR = 1.85; 95% CI = 1.18-2.91; p = 0.0486; p
for trend = 0.0246) or the rs16901979 T (OR = 2.5; 95%CI
= 1.58-3.92; p = 0.0001; p for trend = 0.0001) alleles had a
1.85- to 2.5-fold increase in the risk of developing PCA.
Interestingly, statistical significance was preserved for the
rs16901979T allele after adjusting for potential con-
founders (e.g., age and West African Ancestry) and multi-
ple comparisons. In fact, MDR modeling complemented
with permutation testing identified 8q24 rs16901979 as
the best single factor predictor of PCA risk (p = 0.038), as
noted in Table 3.
Discussion
Sequence variants localized to the 8q24 region have
recently been associated with numerous cancer sites
[4,18,21,22]. In the current study, we evaluated the rela-
tionship between seven sequence variants and the risk of
developing PCA and aggressive disease among 195 cases
and 531 disease-free study participants. Our analyses
revealed a statistically significant 2.5-fold increase in the
risk of developing PCA among men of African descent
who carry the rs16901979 T allele. This relationship
remained important after adjusting for potential con-
founders and multiple comparisons. None of the other six
sequence variants we analyzed were significantly related
to PCA risk.
Our findings on the link between rs16901979 and PCA
risk were validated using MDR, which remains effective
with relatively small sample sizes. In addition, this
observed correlation is further strengthened by two out
of three other studies involving African American men.
These two independent studies both revealed a 1.3- to
1.5-fold increase in the risk of developing PCA with 95%
CIs that exclude unity [6,7].
Several of the evaluated 8q24 SNPs may be more appro-
priate as PCA predictors among men of European- rather
than African descent [3,5,6,11,23]. The rs4242384,
rs4242382, rs1447295, and rs10090154 sequence variants
were not significantly associated with PCA outcomes
among men of African descent in the current study and/
or published reports, but these markers appear to play a
role in PCA risk or aggressive disease among men of
European descent [3,5-7,9,11,19,23-25]. Zheng and co-
workers (2007) observed a 1.3- to 1.9-fold increase inBenford et al. BMC Cancer 2010, 10:334
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Table 2: Association between 8q24 Sequence Variants and Prostate Cancer Risk.
8q24 Cases Controls ORcrude ORadj P-Valuecrude
‡‡ P-Trend
n (%) n (%) (95% CI)† (95% CI) ††
rs6983561
AA 48 (25.8) 171 (33.6) 1.00 1.00 0.0783 0.0246
AC 88 (47.3) 232 (45.7) 1.35 (0.90 - 2.02) 1.78 (1.10 - 2.89) 0.1436
CC 50 (26.9) 105 (20.7) 1.70 (1.07 - 2.70) 1.99 (1.15 - 3.46) 0.0258
AC + CC 138 (74.2) 337 (66.3) 1.46 (1.00 - 2.13) 1. 85 (1.18 - 2.91) 0.0486
rs1447295
GG 86 (45.5) 237 (45.3) 1.00 1.00 0.8742 0.8451
GT 77 (40.7) 221 (42.3) 0.96 (0.67 - 1.37) 0.82 (0.55 - 1.26) 0.8239
TT 26 (13.8) 65 (12.4) 1.10 (0.66 - 1.85) 0.92 (0.49 - 1.70) 0.7121
GT + TT 103 (54.5) 286 (54.7) 0.99 (0.71 - 1.39) 0.86 (0.45 - 1.61) 0.9647
rs4242384
AA 122 (63.2) 383 (73.1) 1.00 1.00 0.0135 0.0515
AC 65 (33.7) 120 (22.9) 1.70 (1.18 - 2.45) 1.50 (0.99 - 2.28) 0.0043
CC 6 (3.1) 21 (4.0) 0.90 (0.35 - 2.27) 0.91 (0.32 - 2.53) 0.8188
AC + CC 71 (36.8) 141 (26.9) 1.58 (1.11 - 2.25) 1.41 (0.95 - 2.11) 0.0101
rs4242382
GG 85 (40.0) 244 (48.1) 1.00 1.00 0.6002
GA 80 (41.5) 191 (37.7) 1.20 (0.84 - 1.72) 1.12 (0.74 - 1.69) 0.3148 0.4655
AA 28 (14.5) 72 (14.2) 1.12 (0.68 - 1.84) 1.05 (0.60 - 1.86) 0.6671
GA + AA 108 (56.0) 326 (51.9) 1.18 (0.85 - 1.65) 1.01 (0.75 - 1.62) 0.3332
rs11934905
GG 173 (94.5) 500 (96.0) 1.00 1.00 0.4161 ---
GA + AA 10 (5.5) 21 (4.0) 1.38 (0.64 - 2.98) 1.83 (0.54 - 6.24)
rs16901979
GG 45 (23.4) 188 (36.7) 1.00 1.00 0.001 0.0002
GT 97 (50.5) 237 (46.3) 1.71 (1.14 - 2.56) 2.28 (1.42 - 3.69) 0.0089
TT 50 (26.1) 87 (17.0) 2.40 (1.49 - 3.87) 3.02 (1.72 - 5.31) 0.0003
GT + TT 147 (76.6) 324 (63.3) 1.90 (1.30 - 2.77) 2.49 (1.58 - 3.92) 0.0001
rs10090154
GG 124 (65.6) 357 (70.7) 1.00 1.00 0.2878 0.2878
GA 59 (31.2) 131 (25.9) 1.30 (0.90 - 1.88) 1.11 (0.72 - 1.69) 0.1676
AA 6 (3.2) 17 (3.4) 1.02 (0.39 - 2.64) 0.88 (0.30 - 2.57) 0.9737
GA + AA 65 (34.4) 148 (29.3) 1.26 (0.89 - 1.81) 1.08 (0.72 - 1.63) 0.1914
†Associations were determined using multivariate LR models to estimate the risk of developing PCA.
††Risk estimates adjusted for age (continuous variable) and West African Ancestry (continuous variable).
‡‡Differences in the frequency of variant and referent genotypes between cases and controls were determined using the chi-square test of 
association and a significance level of 0.05.Benford et al. BMC Cancer 2010, 10:334
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PCA risk among European carriers of one or two
rs4242382 A alleles (OR = 2.90; 95% CIs = 1.02 - 8.25 and
OR = 2.90; 95% CIs = 1.02 - 8.25, respectively) [10,11].
Moreover, Cussenot and co-workers (2008) also demon-
strated a strong relationship between organ-confined
(T1-T2, N0 M0) and advanced (T3-T4, N1M1) PCA among
carriers of 8q24 rs4242382A and rs4242384C alleles [9].
To our knowledge, there are no published reports on the
relationship between the rs11934905 SNP localized to the
8q24 chromosome in relation to PCA among men of
European or African descent.
We have considered the strengths and limitations of the
current study. MDR controls for multiple comparisons
and spurious risk estimates by using a cross validation
and permutation testing scheme as a built-in feature.
Misclassification by case status is also a potential limita-
tion for this study. There is a possibility that some men
who presented as disease-free following the initial diag-
nostic evaluation may eventually develop PCA. In an
attempt to ease case-status misclassification, controls
with at least one abnormal diagnostic test (i.e., PSA > 2.0
ng/ml or irregular DRE) underwent multiple core needle
biopsies. Those with an abnormal biopsy were reclassi-
fied as cases. Men who received a normal biopsy test but
had an abnormal PSA (> 4.0 ng/ml) and/or irregular DRE
(n = 48) were excluded because we could not predict with
any level of certainty whether they would eventually
develop PCA. For similar reasons, we also excluded indi-
viduals (n = 65) who were diagnosed with BPH following
biopsy. Notably, after close inspection of PCA tissue, it is
feasible to overlook a microscopic nodule that can later
develop into cancer [26]; however, this is an issue that
plaques many cancer epidemiology studies. If controls in
our study population were still misclassified after under-
going a PSA test, DRE, and/or multiple core needle biop-
sies, then we may expect our calculated risk estimates to
slightly underestimate the relationship between the
selected 8q24 loci and PCA susceptibility.
Another challenge for genetic epidemiology studies
involving study participants of African descent is their
unique population history of gene flow from divergent
populations [27,28]. The current study adjusted single
locus models for population admixture using a West Afri-
can ancestry score assigned to each study participant.
Utilization of ancestry markers helps to eliminate mis-
classification of study participants based on confusion
related to self-identified race/ethnicity (SIRE). Our find-
ings suggest that adjusting our risk estimates for West
African ancestry did not significantly change the risk esti-
mates relative to unadjusted models; if anything, it makes
them more precise to the nearest tenth.
Finally, it is feasible that the observed association is
related to linkage disequilibrium of rs16901979 with
unknown targets in this region. To address this issue,
future studies will use next generation sequencing tech-
niques to better consider the complete heterogeneity
within this locus relative to PCA outcomes. Emphasis will
be placed on sequence variants within region 3, as it is
speculated that sequence variants may be related to a 2-
fold increase in PCA risk [12,13,29]. Our findings demon-
strating a significant relationship between rs16901979
and PCA risk have been submitted for further validation
within pooled genetic analyses.
Conclusions
In summary, the 8q24 rs16901979 locus has a strong
genetic linkage to PCA among men of African descent in
the current investigation as well as other studies. Future
multicenter collaborative efforts will facilitate the identi-
fication and validation of a reliable panel of genetic sus-
ceptibility biomarkers with the capacity to improve PCA
detection and prognosis strategies, ultimately reducing
PCA health disparities among all men.
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